

Agenda

8:00 - 9:20 am - REGISTRATION / NETWORKING

9:20 - 9:50 am - WELCOME REMARKS

S. TIEN WONG, CEO, Opus8; Founder, Big Idea CONNECTpreneur Forum

BRIAN COBLITZ, Executive Director, Technology Commercialization Office, GWU

EXODIE ROE, Deputy Director for Business & Economic Development, Government of the District of Columbia

JACK MCDUGLE, CEO, Greater Washington Board of Trade

JEFF CHERRY, Managing General Partner, Conscious Venture Partners

PAIGE SOYA, Managing Partner & Chief Investment Officer, K Street Capital

9:50 - 10:40 am - COMPANY SHOWCASE / ROCKET PITCH

Companies will be introduced by:

KEVIN LEES, Partner, Shulman Rogers

DEBBIE CLINE, Founder and Chief of Customer Success, Buzzy Rocket

Animate Biosciences - Peter Licari

Dasion (Data-to-Decision) - Weiqing Gu, PhD

Enamel Pure - Nathan Monty

Endomedix - Richard Russo

Humanetics Corporation - Rear Admiral (Ret) Colin G. Chinn, MD

ImmunoBlue - Lizie Sweeney

NOCTEM Health - Anne Germain, PhD

Pinion Immunotherapeutics - Greg Glenn, MD

True Bearing Diagnostics - Tisha Jepson

10:40 - 12:00 pm - EXPO & NETWORKING

Breakfast and networking in the ballroom

Speakers



TIEN WONG, CEO, Opus8, Inc.

Tien Wong is a private investor and technology entrepreneur focused on early- and growth-stage companies across life sciences, medtech, healthtech, and technology-enabled services. He is Chairman & CEO of Opus8, a capital strategy and investment firm that works with founders, boards, and investors on financing strategy, growth, and strategic positioning. Tien also serves as Executive Chairman of CONNECTpreneur and the New York Private Equity Forum, private capital platforms that convene accredited investors, family offices, and experienced operators around curated investment opportunities. Across these platforms, he has helped build one of the most active private investor communities in the Mid-Atlantic and Northeast. He is a Venture Partner with IronGate Capital Advisors and a member of the Investment Advisory Board of Virginia Venture Partners. Over his career, Tien has arranged or advised on capital from leading institutional investors, family offices, and strategic allocators worldwide.




BRIAN COBLITZ, Executive Director, Technology Commercialization Office, GWU

Brian leads the TCO team in providing best-in-class service to internal and external partners, working toward the commercialization of new technologies invented at the George Washington University. Brian's broad scientific background and angel investing experience contribute to developing relationships between GW faculty and industry licensees. While at GW, he has negotiated multiple license agreements with startups and small businesses and continues to maintain productive partnerships with those developing GW technologies. Brian works to provide ongoing support for GW licensees as they seek funding and expertise on the commercialization pathway. He is a registered patent agent who came to GW in 2012 from the National Institutes of Health's Office of Technology Transfer. Brian received a bachelor's degree from Tulane University, a doctoral degree from Johns Hopkins University's School of Medicine and completed postdoctoral studies on the sense of touch with Dr. Martin Chalfe at Columbia University.



EXODIE ROE, Deputy Director for Business & Economic Development, Government of the District of Columbia

Exodie C. Roe III is a public-private growth leader serving as Deputy Director of Business Development at the Office of the Deputy Mayor for Planning and Economic Development in Washington, DC. In this role, he advances strategies to attract investment, support local businesses, and drive inclusive economic growth across all eight wards of the District. Roe brings senior leadership experience from the U.S. General Services Administration, where he served as a Presidential Appointee and Associate Administrator for Small Business Programs. There, he led initiatives across a multimillion-dollar federal procurement portfolio, expanding access to contracting opportunities and advancing supplier diversity nationwide. Prior to his executive service, Roe held senior policy and advisory roles on Capitol Hill, including serving as Policy Director for the Congressional Black Caucus, where he helped shaped legislative and economic initiatives focused on community development and equitable growth. He is committed to building ecosystems that drive opportunity, strengthen local economies, and create lasting pathways to growth and mobility.



JACK MCDUGLE, CEO, Greater Washington Board of Trade

Jack McDougle is President and CEO of the Greater Washington Board of Trade, where he works with business, government, and academic leaders to drive the region's economic transformation. He focuses on building an economy that is more resilient, inclusive, and fueled by innovation and digital growth. Over his career, Jack has worked across government, business, and the nonprofit sector, giving him a unique perspective on how economies evolve. His experience ranges from shaping national economic policy at the U.S. Department of Commerce to guiding business strategy and transformation in the banking sector. He also played a leading role at the Council on Competitiveness, where he helped craft the first national manufacturing strategy in decades, engaging leaders from industry, labor, government and universities to strengthen America's long-term competitiveness. These diverse experiences inform his leadership today at the Board of Trade, where he works with regional partners to confront challenges such as federal restructuring, disruptive technologies, and the need for smarter infrastructure and workforce strategies. He is a frequent voice on innovation, entrepreneurship, business growth and the future of work, and is deeply engaged in regional collaborations such as the Potomac Regional Alliance.

Speakers



JEFF CHERRY, Managing General Partner, Conscious Venture Partners

Over the last 29 years, Jeff has been a designer, CEO, educator, consultant, and investor. He enjoys the creative process, both from an artistic and organizational perspective. Currently, he's bringing these divergent experiences together in order to help companies develop more conscious, purpose-driven business models; and to help investors build societal as well as financial value. He tries to bring right and left-brain thinking to problem-solve, business creation, and investing ideas; hopefully asking better questions and using his expertise to make the lives of those around him more fulfilling and successful. As the CEO of The Porter Group and Founder and Executive Director of ConsciousVenture Lab, Jeff is an evangelist for the transformation of capitalism. The PorterGroup is a venture capital firm that invests in early-stage and growth-stage companies that are operating at the intersection of profit and purpose. The Conscious Venture Lab is an accelerator for these same types of businesses using the tenets of Conscious Capitalism® and societal purpose as the foundation for creating long-term sustainable value. With the Conscious Venture Lab as an emerging brand in this fast-growing field, Jeff is also a frequently invited speaker on the topic of impact investing and new models of business. He has recently had the honor to present at the University of Maryland, The Darden School at the University of Virginia, Yale University, Columbia University, The Booth School at the University of Chicago, Howard Community College, and The University of Baltimore.



PAIGE SOYA, Managing Partner & Chief Investment Officer, K Street Capital

Paige has served as K Street Capital's Managing Partner since 2018, where she leads the venture investment team and advises on several portfolio company boards. Under her leadership, the firm has deployed capital to over 85 portfolio companies, generating a 26% IRR (2013–2025), with 12 successful exits. She has personally made more than 50 angel investments, including 2 unicorns. Prior to K Street Capital, Paige was a founder, CEO, and strategic advisor with deep operating and transactional experience. She founded and led a SaaS fintech company, which she successfully exited in 2018. As an advisor and acting CFO, she led 12 successful venture funding rounds and six M&A transactions, working with companies ranging from early-stage, venture-backed startups to later-stage private equity-backed businesses. Paige holds an MBA in Finance and a BA in Economics from Johns Hopkins University.



KEVIN LEES, Partner, Shulman Rogers

Kevin Lees has spent nearly two decades helping clients structure, raise and manage private investment funds across a wide range of asset classes. He works with fund sponsors in the United States and around the world, including Latin America, Europe and Asia, including strategies in private equity, buyout, credit, energy, infrastructure, venture capital, real estate, sports, evergreen funds and fund-of-funds structures, as well as joint ventures and small business investment companies (SBICs). Kevin frequently leads cross-border structures involving multiple components and jurisdictions, including Delaware, the Cayman Islands, Luxembourg, Ireland, Canada, the Netherlands, Brazil, Mexico, Spain and Mauritius. He collaborates closely with international counsel to deliver clear, practical guidance tailored to each client's strategy, regulatory needs and investor base.



DEBBIE CLINE, Founder & Chief of Customer Success, Buzzy Rocket

Debbie is co-founder, chief of customer success at Buzzy Rocket and yellow lab lover. From LA to London, she is well known as an expert in creating that certain elusive magic that drives explosive growth at the intersection of companies and customers. She has proven strategic vision, and isn't afraid to get in the trenches. In fact, she's been doing this at companies big and small for 25+ years. Her background includes executive level positions at both public companies and startups where she has proven over and over again that her passion, drive and results oriented perspective get it done. She is tenacious, loves the game changer and loves to win.

OVERVIEW

Animate Biosciences is developing a new class of peptide therapeutics designed to restore healthy tissue repair by reprogramming our body's healing response. By integrating insights from regenerative biology with AI and modern peptide chemistry, Animate designs multi-mechanistic drugs that address healing across organs. Animate's platform is rooted in breakthrough research on super-regenerative species led by Harvard professor and co-founder Dr. Jessica Whited.

UNMET NEED = OPPORTUNITY

Pathological healing underlies many chronic and progressive diseases, contributing to >45% of global mortality.

Current therapies are organ-specific, poorly tolerated, and primarily slow disease progression rather than reverse underlying pathology.

The pathological remodeling market represents a \$200B+ market opportunity, with significant demand for safer, disease-modifying therapies.

ANIMATE PLATFORM & LEAD PROGRAMS

Platform & Technology

Animate's proprietary discovery platform combines:

- Multi-omic datasets derived from super-regenerative species (i.e. axolotl)
- AI-driven peptide design to rapidly identify novel, bioactive sequences
- Advanced solid-phase peptide synthesis enabling rapid design-to-test cycles, often under two weeks

This integrated approach enables rapid discovery of short peptides with multi-mechanistic activity & favorable safety profiles.



Multi-Organ Solution

Animate's lead peptide programs have demonstrated robust anti-inflammatory and anti-fibrotic activity across multiple human cell systems, including lung, heart, liver, and skin models. These peptides suppress key inflammation and fibrotic markers such as α SMA, Col1A1, IL-6, and TNF α .



Effective in Preclinical Animal Models

Animate's lead peptide has demonstrated robust, consistent efficacy across four organ systems, including lung, heart, liver, and skin, with significant reductions in scarring, inflammation, and tissue damage alongside improvements in functional repair.



Protected Intellectual Property

Animate's growing pipeline is protected by three patent filings covering platform technology, composition of matter, and methods of use.

STRATEGY

Animate is raising \$3 million to advance IND-enabling studies and initiate Phase I clinical trials, initially targeting an orphan pulmonary disease indication. Successful clinical validation will support rapid expansion into broader systemic diseases.

CONCLUSION

Animate Biosciences is pioneering a new therapeutic paradigm, restoring healthy healing as a foundation for treating chronic disease by:

- A differentiated AI-driven platform
- Compelling multi-organ preclinical data
- A focused, capital-efficient clinical strategy

Animate is positioned to deliver first-in-class regenerative therapeutics and create substantial clinical and commercial value.

LEADERSHIP

Led by a highly experienced team spanning biologics development, regenerative biology, and company building.

Peter Licari, PhD, MBA (Chief Executive Officer & Co-Founder)

Biochemical engineer with over 3 decades of experience in leadership roles at Merck, BASF, Kosan, Solazyme, and Eat JUST. His experience includes work on approved drug products such as Humira[®] and VAQTA[®].

Jessica Whited, PhD (Chief Scientific Officer & Co-Founder)

Associate professor at Harvard University and a global leader in regenerative species biology.

Jonathan Wolfson, JD, MBA (Executive Chair & Co-Founder)

Serial entrepreneur with a track record of company creation, commercialization, and public exits, including Solazyme's IPO.

DASION – Executive Summary

Company Overview: DASION is building a longitudinal medical intelligence platform powered by its proprietary Geometric Unified Learning (GUL) architecture. Unlike traditional AI systems that rely on static, disease-specific models, DASION models dynamic, time-based health trajectories using geometric biomarkers derived from conversational voice data. This enables continuous, passive monitoring of patient stability without disrupting clinical workflows, creating a scalable foundation for proactive healthcare.

Core Technology: DASION’s VoiceSense platform transforms natural speech into structured, explainable biomarkers capable of detecting early signals of neurological and systemic decline, including stroke risk, cognitive impairment, and depression. By focusing on trajectory shifts rather than point-in-time diagnosis, DASION enables earlier intervention and improved outcomes. Its unified model architecture allows a single system to scale across multiple conditions, significantly improving data efficiency, interpretability, and cost compared to conventional AI approaches.

Traction & Deployment: DASION has demonstrated strong early traction through real-world deployments in post-acute care environments. The company is actively engaged with **16 Skilled Nursing Facilities (SNFs) in Northern California and 17 SNFs in Washington State**, supporting clinical validation and workflow integration. These deployments focus on physician-aligned validation, low false-positive alerting, and seamless integration into existing care systems.

Strategic Partnerships & Market Reach: DASION has established a growing network of strategic collaborations across multiple healthcare systems and regions in the United States, including **California, Nebraska, Virginia, Washington State, and Florida**, spanning hospital systems, skilled nursing facilities, post-acute care networks, and veteran-focused healthcare initiatives. Internationally, DASION is supporting emerging healthcare infrastructure in **Africa**, where its AI platform is being explored for AI-enabled hospital systems.

In parallel, DASION is collaborating with institutional and technology partners to pursue **Rural Health Transformation Funding initiatives and large-scale non-dilutive funding opportunities**, including programs supported by the **National Institutes of Health (NIH)**. These efforts align with expanding access to advanced AI-driven healthcare in underserved and rural populations.

Business Model: DASION operates a B2B licensing and API-driven model, partnering with healthcare providers, payers, and enterprise platforms. Revenue is generated through software licensing, analytics services, and strategic partnerships. Ongoing deployments generate proprietary longitudinal datasets, strengthening model performance and long-term defensibility.

Commercial Progress & Growth Outlook: DASION has secured multiple partnership agreements and is advancing late-stage commercial discussions across healthcare and enterprise sectors. Based on current agreements and pipeline visibility, the company is projecting approximately **\$31.5 million in contracted and prospective revenue over the next 24 months (as of September projection)**. This positions DASION for rapid multi-state and international expansion.

Vision

DASION is building the foundational intelligence layer for continuous health monitoring—transforming voice into a scalable, non-invasive biomarker system that enables earlier intervention, better outcomes, and more efficient healthcare delivery worldwide.



Dr. Weiqing Gu
Data-to-Decision (Dasion)
gu@dasion.ai



Business Plan Summary

Business Overview: Enamel Pure, (EP), is revolutionizing the preventive dentistry market. Current preventive dentistry technology relies on slow manual techniques, is a long and uncomfortable process for the patient and hygienist, resulting in an incomplete cleaning that leads to thin yellow teeth and gum recession. EP’s solution is a combination laser and AI imaging device. The laser modernizes dental cleanings, replaces fluoride with laser hardening, and improves whitening with a mouthguard. The built-in camera produces the first ever AI oral health report and a measurement file that defines orthodontic treatments. The device is twice as fast as existing cleaning techniques, replaces fluoride and whitening care, all while revolutionizing the dental revenue process with an AI health report implementation.



The Company: EP is a seed-stage company having received three FDA clearances. EP has 23 patents filed with 9 issued, and the only competition is the continued use of existing mechanical tools. The pilot manufacturing is complete, and seven dental key opinion leaders have confirmed the device’s efficiency and patient benefits. Three national distributors have signed agreements with EP, so the company is setting up for the first production run in Summer ’26. Nathan Monty, co-founder and CEO, is a serial entrepreneur having sold a business to Danaher Corporation, and started Convergent Dental in Waltham, MA. Chuck Dresser, co-founder and CTO, is a laser medical device expert and a licensed patent agent. The balance of the team specializes in technology, marketing, and regulatory.

The Market: The preventive dentistry market includes teeth cleaning, fluoride treatments, enamel whitening, and orthodontics with Americans spending \$22B yearly, according to the American Dental Association. Worldwide the market segment is about \$50B. 150M+ Americans visit their hygienist bi-yearly, with over 220,000 hygienists in the USA, with teeth cleaning being the largest, by volume, medical procedure in the USA. Revenue is generated by selling the medical device, recurring revenue per clinical procedure, and licensing the use of its AI imaging and orthodontic measurement data.

Value Proposition: The device sells for \$35K per device, or \$850 a month on a 5-year lease. The laser cleaning is twice as fast and quiet, while eliminating pain, bleeding, rinsing and spitting. The laser hardening replaces fluoride treatments, and the whitening is effective while requiring no additional chair time. The built-in camera snaps pictures in between the laser pulses so both cleaning and imaging happen simultaneously. When a patient revisits their hygienist, the previous 3D oral model is compared to the present imaging allowing the AI to diagnose oral health concerns, track clinical results, and predict lifelong health. Lastly, the imaging is converted to a measurement file to define clear aligners and other orthodontic plans. The dental office can reduce cleaning appointment time 30 to 50%, charge for hardening and whitening, and introduce subscription options to aid patients in improving their oral health. Capital equipment, recurring, and data licensing revenue fuel EP’s sales projections.

The Ask. EP has raised \$2.5M and is seeking an additional \$2M. The capital raise is the sale of preferred equity at an \$18M-pre valuation. The raise is to finance the inventory for the initial production run and working capital requirements.

	2024	2025	2026	2027	2028
Units	203	409	826	1388	1680
Sales (\$M)	\$5.8	\$15	\$35.1	\$78.1	\$141.6
EBIT (\$M)	(\$2.7)	(\$2.7)	(\$1.3)	\$7.8	\$27.2

Fun Fact. 40% of USA dentists are women, and a third are minorities. By 2032 half the dentists in America will be women. With the demographic change, dental technology adoption is robust and the dental market is expanding.

Contact

Richard Russo
 President & CEO
 Endomedix, Inc.
 Montclair, NJ 07043
russo@endomedix.com
 Cell : 848 248 1883

Type of Entity

Delaware C Corp

Leadership Team

Richard Russo - CEO
 Piyush Modak- VP, R&D
pmodak@endomedix.com

IP

9 Issued Patents +
 1 application

Company Resources

Lab & Office at Montclair
 State University

Current Investors

3 small funds & angels,
 26 surgeons & physicians
 CEO is lead cash investor.

Prior Financing

NIH SBIR Grants - \$3.2M
 F&F Round \$1.4M

Current Round \$5.4M

- Invested \$4.9M
- Open \$500K

Investment Terms

Premoney valuation - \$7M
 Preferred stock \$1.00 ea. +
 10% warrant coverage
 1x Liquidation preference

Uses of Funds / Next Value Inflection Point

Polysaccharide processing
 scale up
 Dispenser development
 Preclinical studies

Professionals

Legal – Nixon Peabody LLP
 IP – Goodwin Procter LLP
 Acct – JJP Accounting LLP

Overview

Endomedix has developed a new class of absorbable hemostats. Initially targeting neurosurgery, PlexiClot Absorbable Hemostat™ eliminates 3 major sources of bleeding-related complications produced by current methods. These complications cost hospitals hundreds of millions of unreimbursed costs and cause patients to suffer avoidable reoperations and other morbidities. Due to the unique mechanisms of action of its patented biomaterial, PlexiClot introduces the first fundamental innovation in this space since the standard of care was adopted in 1945. PlexiClot leapfrogs current devices & technologies in terms of performance, safety, and ease of use for surgeons. PlexiClot will be the first absorbable hemostat specifically approved for brain surgery by FDA. Endomedix will establish its beachhead in the \$1.9B neuro segment before expanding to other segments of the \$4.5B absorbable hemostat surgical procedure market.

A Big Problem - Current Methods and Results

Bleeding control in brain and spinal CNS surgery is a challenge. Hemostasis must be meticulously complete to avoid major complications. Standard ligature cannot be used, and electrocautery is not appropriate for all bleeding. Current absorbable hemostats have weak slow action, swell in place, and require manual pressure for effectiveness, all contributing to complications. These devices are also opaque (obscuring the surgical field). A study of 7,376 brain surgeries found that bleeding was the number one cause of reoperations within 30 days (5.1%); readmissions within 30 days (11.5%); and hospital stays longer than 10 days (15.6%).

PlexiClot™ Absorbable Hemostat & Progress

PlexiClot is delivered as a spray via a handheld instrument. The spray forms a structured and dynamic device on a bleeding site within seconds. It is not a passive barrier that “waits” for coagulation to occur. Instead it builds upon nature’s methods of clot formation with patented features and is about 20x faster than the standard of care and updates. 9 issued patents protect its composition of matter, method of manufacture, and 4 mechanisms of action. PlexiClot’s performance has been tested on benchtop and 4 large animal trials. The Company has had 3 meetings with FDA to outline testing requirements for superiority claims. A second physical form of the device designed for endoscopic & MIS procedures has been developed and tested.

Market Opportunity & Market Validation

The obtainable serviceable market is 8 million relevant brain & spinal procedures in this \$1.9B segment. To date, 26 surgeons & physicians have invested \$2M in equity and NIH has awarded the Company 7 competitive SBIR grants.

Leadership Team

CEO is a 35+ year Medtech vet with success in new products & two prior start-ups with successful exits. Strong regulatory, clinical & international experience. VP-R&D is an accomplished biomaterial scientist, main inventor of technology platform, led product development program. Company uses lean internal staff leveraged via renown consulting scientists and leading clinical advisors.

Financial Projections – 000’s omitted (USD \$)

	Year 1	Year 2	Year 3	Year 4	Year 5	Year 6	Year 7	Year 8
Revenue	-	-	-	1,786	25,225	82,197	142,136	207,277
Gross Margin	-	-	-	44%	68%	72%	72%	72%
Op Exp.	1,464	3,900	4,864	9,353	16,432	26,615	37,084	46,282
EBIT	(1,464)	(4,024)	(5,131)	(8,569)	831	32,332	65,813	103,514

- *Advanced clinical stage*
- *Dual use drug:
warfighters & civilians*
- *Near-term revenue*

KEY FACTS

- \$155M Capitalization
 - \$100M Non-dilutive
 - \$ 55M Equity
- Fully funded to Emergency Use Authorization
- Commercial revenue within 24 months
- 19 issued / 8 pending patents
- Orphan Drug; FDA Fast Track
- NDAA FY26 Congressional Testimony

MANAGEMENT TEAM



Ronald Zenk, CEO
Founder; DoD Licensing Liaison; \$45M Appropriations



Adm Colin Chinn, MD, CMO 38 Years Navy fmr Jt Staff Surgeon, Pentagon 2017–2019



Michael Kaytor, PhD, CSO Biochemistry and Biophysics; \$45M NIH Funding Lead



Timothy Morris, COO Served as CFO, COO for multiple public pharma companies

BOARD OF DIRECTORS

- Adm. Matt Nathan, MD, Chairman 37th Surgeon General US Navy
- Gen. Barbara Holcomb, fmr Commander, U.S. Army Medical Research and Materiel Command
- Jake Nunn, MBA, Cap'l Mkts Partner, SR One; fmr Partner, NEA
- Thomas Jasper, CPA, COO Choice Bank
- John Dykstra, fmr COO Humanetics

COMPANY OVERVIEW

Humanetics is a clinical-stage specialty pharma company developing **BIO 300 (aka BYOGRAYZ™)**, the most advanced drug in the industry to prevent radiation damage, also referred to as a RadioProtectant.

PROBLEM: TOXIC RADIATION



Warfighters



Nuclear Power Facilities




Cancer Radiation Therapy

Global threats of toxic radiation are rising; there is no available agent to protect military and civilian populations from harm. Likewise, there is no approved drug to protect healthy tissue from the harmful effects of cancer radiation therapy.

BYOGRAYZ: A POWERFUL NEW RADIOPROTECTANT

- Developed by U.S. Military; licensed to Humanetics
- Whole body protection
- Self-administered daily oral dosing (< one tablespoon)
- No needles, syringes, or refrigeration

DUAL USE MARKET OPPORTUNITIES



Medical Countermeasure

U.S. Military: \$126M
U.S. HHS (Civilians): \$590M
EU; Middle East; Asia: \$290M

Cancer Radiation Therapy (Cases; US)

1. Lung: 100,000/yr; \$1.6B
2. Head & Neck: 50,000/yr; \$725M
3. Prostate: 150,000/yr; \$4.0B

CLINICAL DATA IN FOUR TRIALS; ROBUST SAFETY PROFILE

- Phase 1b/2a in NSCLC: lower adverse event rates; improved tumor response; no dose limiting toxicities reported
- Phase 2 in Long COVID: improved pulmonary function and QoL; well-tolerated

SERIES B PREFERRED (UP TO \$10M)

- Supports Phase 2 clinical development in cancer and pulmonary indications



ImmunoBlue

IB-T cells for Glioblastoma



Lizie Sweeney, PhD
CEO



Rohan Fernandes, PhD
CSO, Founder



Varnika Roy, PhD
Head of Development


ImmunoBlue is led by a multidisciplinary team with deep expertise in bioengineering, cell therapy, and translational development. Combined, >\$5M raised, 60+ publications, and 6+ patents with exclusive IP option.

PROBLEM: GBM is fatal

- Glioblastoma (GBM) is the most common malignant brain tumor in the U.S. (>13,000 new cases/year).
- Outcomes remain extremely poor: **five-year survival is ~7.5%, and >90% of patients relapse.**
- Standards of care (surgery, radiation, chemo) have not changed in decades and fail to deliver durable disease control.

SOLUTION: IB-T cells for GBM

- IB-T cells^{1,2} are a **first-in-class autologous T cell therapy.**
- Nanoparticle-driven photothermal conditioning of a patient's own tumor tissue reveals the full set of immune signals, enabling expansion of T cells that recognize many tumor targets simultaneously.
- The result is a personalized, multi-targeted immune response that is harder for tumors to escape.
- This platform extends beyond GBM to other solid tumors.



MARKET SIZE: \$6B


- Entry market is 2nd line therapy for recurrent GBM.
- At ~12,564 recurrent patients per year in the US and the current benchmark price of T cell therapy at \$475,000, **estimated annual addressable market of \$6B.**
- Market expansion into newly diagnosed disease and other solid tumor indications.

COMPETITIVE ADVANTAGE

	Activated and scalable	Multiple targets	Personalized	Novel antigen discovery
CAR T cells	✓	✗	✗	✗
Multi-antigen-specific T cells	✓	✓	✗	✗
Tumor-infiltrating lymphocytes (TILs)	✗	✓	✓	✗
IB-T cells	✓	✓	✓	✓

PRECLINICAL IN VIVO VALIDATION

IB-T cells cure >80% of mice with GBM



DEVELOPMENT PLAN: Targeting \$10M Raise

- NCI Phase I & II STTR funding secured (**\$2.7M**)
- IND-enabling studies and GMP manufacturing underway
- Clinical partners (Rutgers Cancer Institute) and advisory team in place
 - Experts in neurosurgery, neuro-oncology, cellular immunotherapy, and cellular manufacturing
- Orphan Drug Designation and IND submission planned
- **Seeking \$10M to fund first-in-human Phase 1 clinical trial in recurrent GBM**

¹ Sweeney, et al. *Cytotherapy*, 2023.

² Sweeney, et al. *Bioengineering & Translational Medicine*, 2023.



**Provider-Supervised, Tech-Enabled
Insomnia Care at Scale**

www.noctemhealth.com

Founded: 2021

Industry Focus: Sleep Medicine

Indications

- Behavioral sleep medicine
- Remote therapeutic monitoring
- Sleep & performance optimization

FDA Status: Clinical decision support platform under enforcement discretion

Non-Dilutive Funding to Date: \$4.5M

Fundraising: \$1M USD (Priced Round)

Use of Funds:

- Accelerate commercial traction
- Product Support for Growth

Product:

- Software: COAST[®]
(Clinician-Operated Assistive Sleep Technology)

Current COAST Subscribers:

- 21 tier-1 Clinics in USA & Canada

2025 Revenue:

- SaaS Subscription: \$190K
- SaaS-Related Services: \$50K
- R&D (product customization): \$413K

Competitors

- Big Health (Sleepio)
- DrLullaby, Inc.
- Sleep Reset, Inc

CONTACT

Anne Germain, PhD
Cell: +1-412-212-3077
anne@noctemhealth.com

NOCTEM[®] Health Inc. creates sustainable, clinically validated solutions to address the global insomnia problem.

PROBLEM

Insomnia affects 30% of the global population. The best insomnia therapy is burdensome and offered by fewer than 500 specialists worldwide. Every untreated patient represents lost revenue, but healthcare providers don't have the tools to offer the first-line insomnia therapy at scale.

SOLUTION & BENEFITS

COAST[®] makes the first-line insomnia therapy accessible to all healthcare providers and their patients, creating new revenue-generating opportunities.

COAST is the first clinical decision support (CDS) platform in behavioral sleep medicine. Our algorithms upskill healthcare providers, allowing them to deliver high-quality sleep care at scale, with the right financial incentives.



COMPETITIVE ADVANTAGES

- FDA 513(g) determination completed
- World renowned expertise and know-how in productizing complex clinical workflows; trademarks
- Clinically validated solutions
- Proprietary intervention modules
- Demonstrated product-workflow fit

MARKET SIZE

NOCTEM's initial GTM segment focuses on sleep, behavioral health, and women's health clinics represent total addressable market of **\$4.8B**. NOCTEM will leverage its fast-growing traction to penetrate health plans and "payviders" and self-insured employers, which represent a combined \$5.2B opportunity. Partnerships with leaders in sleep apnea treatment devices, telehealth providers, and/or consumer-focused sleep tech devices can unlock additional markets and opportunities exceeding \$5B.

LEADERSHIP TEAM

Anne Germain, PhD: Founder & CEO

World renowned subject matter expert in behavioral sleep medicine; 200+ publications; 25 years executive, operations, and clinical leadership.

Megan Wolfson, LCSW: Clinical Operations

Digital behavioral sleep medicine expert, clinical operations and customer success

Christopher Herman: Principal Developer

10+ years software development; cloud infrastructure

Seth Zimmerman, JD, MBA: Fractional CFO

15- years of leadership in early-stage tech companies: growth, fundraising, and successful exits.

Carpe Noctem![®]

PINION IMMUNOTHERAPEUTICS

Executive Summary | Series A Financing · PIN-001 (ARV-2001) HPV-16 Therapeutic Vaccine | 10 April 26

Company Overview

Pinion Immunotherapeutics is a clinical-stage mRNA-LNP immunotherapy company based in North Bethesda, MD. Led by CEO Gregory Glenn, MD (former President of R&D at Novavax) Pinion is developing a pipeline of mRNA-based therapeutic vaccines targeting chronic infection-driven diseases and cancers.

Pinion's lead program, PIN-001 (ARV-2001), is a mRNA-LNP therapeutic vaccine for HPV-16+ cervical high-precancers (cHSIL / CIN2/3); FDA-cleared IND as of Jan 2026 and Phase 1/2 initiation planned for Q2–Q3 2026.

The Problem & Market Opportunity (ARV 2001)

- HPV16-driven precancer (cHSIL/CIN2/3) affects hundreds of thousands of US women annually — the cancer precursor at a 9:1 ratio to invasive cervical cancer.
- The current standard of care, LEEP (Loop Electrosurgical Excision Procedure), is performed in ~250,000+ US cases per year and carries recurrence rates ~25%; risks of cervical insufficiency, preterm birth.
- Prior therapeutic HPV vaccine trials (protein, viral vector, DNA) demonstrated proof of concept but fell short of clinical efficacy thresholds. mRNA-LNP technology now provides the potency to cross that threshold.

Scientific Differentiation — ARV-2001

- mRNA-LNP platform encoding HPV-16 E6/E7 antigens, delivered ID for superior CD8+ T cell induction.
- Proprietary combination of an Immune Response Enhancer (IRE) and T-cell Infiltrating Enhancer (TIE) drives tumor-infiltrating lymphocyte expansion and precancer clearance.
- Three decades of therapeutic HPV vaccine science have validated the T-cell mechanism — ARV-2001 applies best-in-class mRNA technology to a de-risked biology.

Pipeline

Program	Indication	Stage	Timeline
PIN-001 (ARV-2001)	HPV-16+ Cervical Precancer (cHSIL/CIN2/3)	Phase I/II	Q3 2026 Start
ARV-1004	EBV: Infectious Mono, MS, Periodontitis	IND Enabling	2026–2027
ARV-1002	HSV: Genital Herpes, Neonatal Herpes	IND Enabling	2026–2027
DCAR-001/002	AML; KRAS-mutant PDAC / Colorectal CA	Discovery	2026–2027

Series A Financing — \$20M

Structure	Two tranches, milestone-gated
Tranche 1 — \$6M	Phase I activation & enrollment (Q3 2026): safety and immunogenicity data
Tranche 2 — \$14M	Phase II efficacy study + IND safety bridging study & FDA interaction (Q4 2026)
Status	Lead investor committed \$6.5M total; seeking \$3M to close Tranche 1
Key Milestones	Phase I safety data Q4 2026 · Phase II efficacy readout Q4 2027

Leadership & Advisors

Leadership Team Gregory Glenn, MD — CEO (IOMAI, Novavax) Jianzhu Chen, PhD — Co-Founder & Board Chair (MIT Koch Institute) Renhuan Xu, PhD — CSO & Co-Founder Regina Jakacki, MD — CMO (AZ, J&J, CHOP)	Strategic Advisors Phil Krause, MD — Regulatory (Former Deputy Director, FDA CBER) Robert Redfield, MD — PHS (Former CDC Director) James Young, PhD — Former President R&D, Medi Richard Douglas, PhD — Corp. Dev; NVAX, Genzyme
---	---



TRUE BEARING DIAGNOSTICS, INC.

Executive Summary

April 2026

Company

True Bearing Diagnostics, Inc. (the “True Bearing”) is developing *TruNAV™*, the world’s first highly accurate, host driven, RNA derived, blood based diagnostic tool designed for infection detection. *TruNAV™* will offer an agnostic approach diagnosing infection, selecting which basic type is involved (bacterial, viral, and/or biofilm), and measuring the infection’s magnitude for ease of tracking therapies like antibiotics.

True Bearing was incorporated in 2017 to extend and commercialize certain research breakthroughs developed by the St. Laurent Institute and George Washington University’s Center for Genomic Medicine. True Bearing’s mission is to introduce a collection of RNA-based blood tests that will drastically decrease the costs associated with the early-detection and treatment of multiple diseases and infections.

True Bearing started with a focus on coronary artery disease and, in 2020, with the arrival of COVID, pivoted to the diagnosis of infection. Overall, True Bearing is developing bio-marker panels that, it believes, will revolutionize the diagnosis across multiple diseases, *offering increased accuracy, delivered faster and cheaper.*

Highlights

- **Binary Decision and Magnitude of Infection**
Doctors lack a clear non-invasive tool to determine if infection is present or not. If present, what is its magnitude? Our greater than 90% accurate test allows for more effective, efficient results and diagnosis, enabling faster paths to addressing patient needs (including chronic abdominal pain, chronic sinus pain, hospital derived infection, orthopedic parts, appendicitis, urinary tract infections, biofilm, among others).
- **Solid Scientific Basis**
True Bearing has several publications with multiple research studies’ confirmed data sets and patent coverage.
- **Over \$100 billion potential savings** in the US alone¹.
- **Population Scale Triage Diagnostic**
Immediate diagnostic response offers identification and quarantine of sick people allowing for more efficient and effective treatment with minimal impact on economies.
- **Competitive Landscape**
Currently available tools include white blood cell count (+/- 60% accurate), CT scan (expensive), exploratory surgery (expensive and invasive). **We are offering a better test within an already existing market.**

Large Addressable Markets

The global infectious disease in-vitro diagnostics market size in 2023 was \$77.9 billion² and is expected to grow by 4.5% (CAGR) annually through 2033. Growth is attributed to growing elderly population, technology advancements and increased funding for R&D in addition to increased public awareness and the push for Point of Care, (PoC) testing, lower cost solutions, AI inputs, and automation.

While the overall infectious disease market is very large, to facilitate the FDA Clearance process True Bearing’s initial focus area is “assisting with diagnosis of abdominal infection” which is a \$5.1 billion current addressable market.

Investment Opportunity

Building upon True Bearing’s lead investor’s initial contributions and with next round participation committed, the Company closed on initial tranche and seeks to complete raise ~\$5 million in funding. With this infusion, True Bearing will be able to rapidly perform *TruNAV™*’s FDA clearance study, set up and/or align with a CLIA lab, develop payor relationships, and position itself for alignment with a strategic partner or sponsor.

Following FDA Clearance, next step Series-A equity financing and/or strategic partnership will enable an acceleration of expanded research, pipeline development, and scaled commercialization with a 5-year estimated trajectory as outlined below. We believe True Bearing estimates are conservative and include having analyzed real test sales ramp numbers from industry leaders including Veracyte - Afirma, Genomic Health - Oncotype DX, and Vermillion - Ova1.

Post FDA Clearance					
(\$ in millions)	Year 1	Year 2	Year 3	Year 4	Year 5
Revenue	\$9.7	\$16.2	\$51.7	\$135.7	\$193.9

Business Model

- Funding enables new lab setup, FDA clearance process, and payor relationship development.
- Leverage our partnerships with hospital groups and Key Opinion and industry Leaders participating in *TruNAV™* FDA clearance validation study.
- FDA clearance and next larger round capital raise achieved – Launch early sales and marketing plan and commence post market studies. In addition, continue ongoing expanded research and pipeline development.
- Exit potential with licensing, strategic partner purchase, or IPO 1-2 years post FDA Clearance.

Our Partners



THE GEORGE WASHINGTON UNIVERSITY OFFICE OF INNOVATION & ENTREPRENEURSHIP

The George Washington University (GW) Office of Innovation & Entrepreneurship provides programming around innovation, education, venture creation, and making connections to support GW entrepreneurs and the Mid-Atlantic startup community. Founded in 2010, the office has worked with thousands of students, faculty, and alumni, and serves as a focal point for entrepreneurship at GW. It leverages the unique strengths of our university's schools in the nation's capital to serve society at large through the knowledge and practice of entrepreneurship.



NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior services across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.



BUZZY ROCKET

Buzzy Rocket was founded 12 years ago with the mission to help startups grow and scale their businesses. Debbie and Victoria do this with their decades of marketing experience combined with their first hand experience founding, growing and scaling successful startups. They only work with 6 startups at any given time so they can provide 1:1 attention to you and your team. The Buzzy Rocket team is also made up of web developers, graphic designers and copywriters so they can help you easily execute the marketing strategy they create. Learn more about their services at BuzzyRocket.com.



NFP

NFP is a leading insurance broker and consultant that cares deeply about our employees' and clients' well-being. We're honest, hardworking, dedicated professionals who love what we do and strive to lead by example. But what truly defines us is that for us, business is personal. At the end of the day, our vision isn't a financial metric or a top 10 list. It's that when you hear "NFP," you think of a world-class company that's authentic, genuine and real. One whose expertise and scale are only matched by its passion for building lifelong personal relationships.



INES LEBOW, Founder and Principal, Enterprise Transformation Solutions

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.



APRIL 16 HOST COMMITTEE



**SCOTT
ALFORD**

Oracle Capital



**THOMAS
ANDERSON**

DataStrategi



**MARCO
AVILA**

MDHCC / WSP



**ERIKA
BAEZ-GRIMES**

Silver Tsunami
Transitions



**JEFF
CHERRY**

Conscious Venture
Partners



**TASHA
CORNISH**

Cybersecurity
Association



**JOHN
DIERKES**

Pickwick Capital
Partners



**CHRIS
FREW**

BioBuzz



**JAMES
GIBBONS**

Alpha Pointe
Capital



**ANITA
GUPTA**

KiwiTech



**DEBORAH
HEMINGWAY**

Ephora Capital



**MIA
HORM**

Creative
Analytics



**NICHOLE
KELLY**

Innovation
Maryland



**MATTHEW
LEE**

FASTech




**MIKE
MALLOY**

Malloy
Industries



**LAURA
NEUMAN**

NextGen Venture
Partners



**GUC
OZENCI**

Founder Institute



**JOHN
YETMAN**

CEO Stories

THANK YOU TO OUR PREP TEAM



LISA FRIEDLANDER
Co-Founder
My NEXT Raise



MICHAEL HANSON
Consultant
Optimum Dynamics LLC



INES LEBOW
CEO
Enterprise Transformation
Solutions



MARISSA LEVIN
CEO
Marissa International



JET LU
Customer Solutions
Amazon Web Services



JACKIE LUO
Founder
BAM Advisory



MICHELLE MILLER
Founder
MRM Consulting



JOHN MORGAN
General Partner
Morgan Global



EVAN SHUBIN
Pres. and Founder
Results.now, Inc. and
Candlelight Partners



MALI PHONPADITH
CEO
SOAR Community
Network



MICHAEL RIEMER
CEO & Board Member
Vocinity

Big Idea
CONNECTpreneur

**UPCOMING VIRTUAL
INVESTOR EVENT!**

May 28
Online via Zoom



**LIFE SCIENCE
INVESTOR RECEPTION**

June 22
San Diego, CA



**NEWPORT BEACH
INVESTOR CONFERENCE**

June 25
Online & In-Person (CA)





VIRTUAL AND IN-PERSON

CALL FOR PRESENTERS

Unprecedented
**Networking
sessions**
before, during, and
after each event

Free lifetime
admission
to all
CONNECTpreneur
Forums

Post-event recap to
**300k business
leaders**
in our Community

SCAN HERE FOR
THE IN-PERSON
BROCHURE:



SCAN HERE FOR
THE VIRTUAL
BROCHURE:



Get funded with our



Private Investor Platform



One of the nations largest investor communities of 4,500+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.

**Exclusive,
cost effective,
& reliable**

**Vetted, qualified,
accredited
Investors**

**We
guarantee
our results**



**View the full
brochure**

Tien Wong
CEO
twong@opus8.com

Skylar Rallison
Community Manager
srallison@opus8.com

● SUPERCHARGE YOUR
RAISE WITH OUR

CROWDFUNDING SERVICES

We combine high-impact messaging, investor psychology, and access to our unique community of over 315,000 accredited and retail investors, business leaders, and influencers.

WHAT WE OFFER

- ✓ Dedicated Email Blasts
- ✓ Multi-Email Drip Campaigns
- ✓ Campaign Strategy Support
- ✓ Video and Page Feedback
- ✓ Live Investor Engagement Opportunities



View the full
brochure

Thank you to our Partners



CONNECT with us!

